Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1632 1645 1648 1671 1672
This examiner grants 58% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17670091 | PRIMER DESIGN AND USE FOR LOOP-MEDIATED ISOTHERMAL AMPLIFICATION (LAMP) PATHOGEN DETECTION | Non-Final OA | Purdue Research Foundation |
| 17783038 | GENE TRANSFER SYSTEM | Final Rejection | The University of North Carolina at Chapel Hill |
| 18296357 | ANALYSIS OF VIRAL PARTICLES BY DIGITAL ASSAY | Non-Final OA | Bio-Rad Laboratories, Inc. |
| 17996797 | LIPID NANOPILLAR ARRAY-BASED IMMUNOASSAY | Non-Final OA | KOREA INSTITUTE OF MACHINERY & MATERIALS |
| 17679521 | METHODS AND SYSTEMS FOR PERFORMING A PATIENT-SPECIFIC IMMUNOTHERAPY PROCEDURE WITH CHAIN-OF-CUSTODY AND CHAIN-OF-IDENTITY BIOLOGICAL SAMPLE TRACKING | Final Rejection | Kite Pharma, Inc. |
| 18511486 | Minimal Human-Derived Virus-Like Particles and Methods of Use Thereof for Delivery of Biomolecules | Non-Final OA | The General Hospital Corporation |
| 17603302 | MODIFIED AAV VECTORS THAT DAMPEN THE HUMORAL IMMUNE RESPONSE | Non-Final OA | University of Florida Research Foundation, Incorporated |
| 17627854 | HOST-INDEPENDENT EXPRESSION OF BACTERIOPHAGES | Non-Final OA | TECHNISCHE UNIVERSITÄT MÜNCHEN |
| 17534043 | Methods and Systems for the Detection of Microorganisms Using Infectious Agents | Non-Final OA | Laboratory Corporation of America Holdings |
| 17998592 | STABILIZED CORONAVIRUS SPIKE PROTEIN FUSION PROTEINS | Non-Final OA | Janssen Pharmaceuticals, Inc. |
| 16327473 | 2D ORGANOID FOR INFECTION AND CULTURE OF HUMAN DIARRHEA VIRUS, AND USE OF SAID 2D ORGANOID | Non-Final OA | Keio University |
| 17048297 | IMMUNO-ONCOLYTIC MODIFIED VACCINIA TIAN TAN VIRUS AND METHODS OF TREATING CANCER | Final Rejection | The University of Hong Kong |
| 18008526 | VIRUS PURIFICATION METHOD USING APATITE COLUMN | Final Rejection | HOYA TECHNOSURGICAL CORPORATION |
| 18054212 | PREPARATION METHOD OF ARTIFICIAL ANTIBODY | Non-Final OA | BINGHUAN WENG |
| 18250685 | REPORTER MYCOBACTERIOPHAGE, ASSAYS AND METHODS COMPRISING THE REPORTER MYCOBACTERIOPHAGE | Non-Final OA | Albert Einstein College of Medicine |
| 17905040 | METHOD FOR PRODUCING INACTIVATED INFLUENZA VACCINE AND VACCINE COMPOSITION THEREOF | Final Rejection | DENKA COMPANY LIMITED |
| 18008391 | IDENTIFICATION OF LOW-DENSITY INFLAMMATORY NEUTROPHILS IN SEVERE COVID-19 PATIENTS | Non-Final OA | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. |
| 17262098 | ANTIGEN PURIFICATION METHOD | Final Rejection | GLAXOSMITHKLINE BIOLOGICALS SA |
| 18458108 | EPSTEIN BARR VIRUS VACCINES | Non-Final OA | Fred Hutchinson Cancer Center |
| 18473956 | COMPOSITIONS FOR CORONAVIRUS DETECTION AND METHODS OF MAKING AND USING THEROF | Non-Final OA | THE HOSPITAL AUTHORITY |
| 18280150 | FULLY SYNTHETIC, LONG-CHAIN NUCLEIC ACID FOR VACCINE PRODUCTION TO PROTECT AGAINST CORONAVIRUSES | Non-Final OA | ROCKETVAX AG |
| 17909145 | FULLY SYNTHETIC, LONG-CHAIN NUCLEIC ACID FOR VACCINE PRODUCTION TO PROTECT AGAINST CORONAVIRUSES | Non-Final OA | ROCKETVAX AG |
| 18278191 | AN ISOLATED POLYPEPTIDE | Non-Final OA | UNIVERSITY OF ULSTER |
| 18014947 | Severe Acute Respiratory Syndrome Coronavirus 2 (SARS CoV-2) Peptide Epitopes | Non-Final OA | The Brigham and Women`s Hospital, Inc. |
| 17108183 | VIRAL VECTOR PURIFICATION APPARATUS AND METHOD | Final Rejection | GLOBAL LIFE SCIENCES SOLUTIONS USA LLC |
| 18267710 | Use of fibrin-targeting immunotherapy to reduce Coronavirus pathogenesis | Non-Final OA | The J. David Gladstone Institutes, a testamentary trust established under the Will of J. David |
| 18250621 | CHICKEN ANEMIA VIRUS (CAV)-BASED VECTORS | Non-Final OA | FLAGSHIP PIONEERING INNOVATIONS V, INC. |
| 18004719 | METHODS FOR IDENTIFYING CORONAVIRUS CROSS-REACTING ANTIBODIES | Final Rejection | LEYDEN LABORATORIES B.V. |
| 17921672 | NASAL-SPRAY SAMPLING | Non-Final OA | HERO SCIENTIFIC LTD. |
| 17688960 | INACTIVATION PROCESS FOR VIRUSES | Non-Final OA | Valneva Austria GmbH |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy